Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adenocarcinoma of the Rectum Clear all
Terminated Phase 2 Interventional Results available

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

NCT00390364
View directory record Official record
Conditions
Colorectal Cancer
Interventions
everolimus, antiangiogenesis therapy, biopsy, diagnostic procedure, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis, protein tyrosine kinase inhibitor therapy, reverse transcriptase-polymerase chain reaction
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Jul 21, 2026, 12:06 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

NCT00321685
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
Interventions
Bevacizumab, Capecitabine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, Radiation Therapy, Therapeutic Conventional Surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
107
States / cities
Birmingham, Alabama • New Britain, Connecticut • Atlanta, Georgia + 66 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Jul 21, 2026, 12:06 PM EDT
Completed Phase 2 Interventional Results available

Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

NCT01802320
View directory record Official record
Conditions
Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Jul 21, 2026, 12:06 PM EDT
Completed Phase 1 Interventional

TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

NCT03297710
View directory record Official record
Conditions
Rectal Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IV Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
Interventions
Quality-of-Life Assessment, Radiation Therapy, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Other · Radiation · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Jul 21, 2026, 12:06 PM EDT
Completed Phase 1 Interventional

Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer

NCT01383343
View directory record Official record
Conditions
Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
Bevacizumab, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Sorafenib Tosylate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Jul 21, 2026, 12:06 PM EDT
Completed Phase 2 Interventional

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

NCT00096083
View directory record Official record
Conditions
Cancer
Interventions
isolated perfusion, melphalan
Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Jul 21, 2026, 12:06 PM EDT
Completed Phase 1 Interventional

A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer

NCT05130060
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Microsatellite Stable Colon Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Microsatellite Stable Rectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Colorectal Cancer Peptide Vaccine PolyPEPI1018, Trifluridine and Tipiracil Hydrochloride
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Jul 21, 2026, 12:06 PM EDT
Recruiting Phase 1 Interventional

Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial

NCT06834126
View directory record Official record
Conditions
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Consolidation Therapy, Functional Magnetic Resonance Imaging, Gastrointestinal Endoscopy, Magnetic Resonance Imaging, Papaverine, Radiation Therapy, Total Mesorectal Excision
Procedure · Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jul 21, 2026, 12:06 PM EDT
Withdrawn Phase 2 Interventional

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

NCT05356897
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC V8, Stage IV Colorectal Cancer AJCC V8, Stage IV Rectal Cancer AJCC V8
Interventions
Trastuzumab, Trifluridine and Tipiracil Hydrochloride, Tucatinib
Biological · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
San Diego, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 21, 2026, 12:06 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma

NCT01302613
View directory record Official record
Conditions
Stage II Rectal Cancer, Stage III Rectal Cancer
Interventions
Capecitabine, 5-FU, Leucovorin, Oxaliplatin, radiation, total mesorectal excision
Drug · Radiation · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Jul 21, 2026, 12:06 PM EDT
Active, not recruiting Phase 2 Interventional

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

NCT00492999
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
dexamethasone, floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 21, 2026, 12:06 PM EDT
Terminated Phase 2 Interventional Results available

Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

NCT03592641
View directory record Official record
Conditions
Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Savolitinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
33
States / cities
Los Angeles, California • Sacramento, California • Derby, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Jul 21, 2026, 12:06 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Therapy for Localized Rectal Adenocarcinoma

NCT04418895
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Chemoradiation, short course radiation therapy, mFOLFOX6, CAPOX, fluoropyrimidine +/- oxaliplatin
Other · Radiation · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Jul 21, 2026, 12:06 PM EDT
Active, not recruiting Phase 1 Interventional

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

NCT04104139
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Trifluridine and Tipiracil Hydrochloride
Radiation · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 21, 2026, 12:06 PM EDT
Completed Phase 1 Interventional

Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer

NCT00059930
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFOX regimen, dexamethasone, floxuridine, fluorouracil, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2025
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Jul 21, 2026, 12:06 PM EDT
Completed Phase 1 Interventional

Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer

NCT00656123
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
Colon GVAX, cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jul 21, 2026, 12:06 PM EDT
Completed Phase 3 Interventional Results available

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

NCT00911170
View directory record Official record
Conditions
Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
Interventions
Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
72
States / cities
Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Jul 21, 2026, 12:06 PM EDT
Terminated No phase listed Observational Results available

Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

NCT03765736
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Genetic Testing
Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Jul 21, 2026, 12:06 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

NCT07292298
View directory record Official record
Conditions
Rectal Adenocarcinoma, Rectal Cancer
Interventions
High Rare Dose Rectal Brachytherapy Boost
Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Aurora, Colorado • Rochester, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 21, 2026, 12:06 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma

NCT01634685
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Radiation, Bavituximab, Capecitabine
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Jul 21, 2026, 12:06 PM EDT
Completed Phase 3 Interventional Results available

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

NCT00265850
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, cetuximab, FOLFOX or, FOLFIRI
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
2,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
662
States / cities
Mobile, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 468 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Jul 21, 2026, 12:06 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery

NCT00290615
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, cetuximab, capecitabine, oxaliplatin
Biological · Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Jul 21, 2026, 12:06 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated

NCT00025337
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Jul 21, 2026, 12:06 PM EDT
Terminated Phase 2 Interventional

MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

NCT00602329
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, fluorouracil, leucovorin calcium, oxaliplatin
Biological · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Jul 21, 2026, 12:06 PM EDT